Two very different HALEU supply stories converged this month around a single theme: buyers are locking in fuel years before it exists.
In South Africa, future production from the planned QLE–Necsa HALEU enrichment facility at Pelindaba is already backed by supply offtake agreements with TerraPower, the US advanced reactor developer behind the Natrium system. The joint venture between Quantum Leap Energy, a subsidiary of ASP Isotopes, and state-owned Necsa was announced on 20–21 October 2026 — and it arrives with demand already contracted.
Centrus stacks up developer deals
Centrus Energy has been assembling a comparable book of agreements in the United States. Over recent months the company announced multiple fuel supply agreements with advanced reactor developers including Oklo, X-energy, Radiant and Antares, with deliveries planned before the end of the decade. Those deals underpin Centrus's position as the leading prospective domestic HALEU supplier.
The underlying demand signal is structural: nine of the ten reactor designs supported under the US Department of Energy's Advanced Reactor Demonstration Program require HALEU.
A supplier in transition
Centrus has traditionally operated as a nuclear fuel supplier, purchasing low-enriched uranium (LEU) from international enrichers under long-term supply agreements. It is now transitioning into a domestic uranium enricher. The company is the only firm currently holding a US Nuclear Regulatory Commission licence with deployable gas centrifuge technology capable of enriching uranium to both LEU and HALEU — a position that becomes more valuable as the US Prohibiting Russian Uranium Imports Act takes full effect in 2028.
The cost of building capacity
That transition is capital-intensive. Scaling manufacturing to become a domestic producer is expected to weigh on earnings over the next several years, even as the contract book grows.
Markets have repriced the theme. Centrus shares traded near $108.91, down about 0.9% on the day, with a market capitalisation of roughly $2.25bn and a 52-week range of $106 to $402. Centrus and BWX Technologies both rallied last year on the nuclear renaissance narrative, but have fallen 54% and 22% respectively in 2026.
Centrus is scheduled to report third-quarter 2026 results after market close on 4 November, with a conference call for shareholders and the financial community on 5 November at 8:30 a.m. ET.
This article was assisted by AI analysis. Please refer to the original source for official information.